Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial

Table 4 Evolution of hemodynamic status from day 1 to day 14

Outcomes	Day 1	Day 7	Day 14	Difference between groups^b
Outcomes	Mean ± SD	Mean ± SD	Mean ± SD	Mean	95%CI	p-value
Temperature (°C)
Treatment	36.54 ± 0.66	36.40 ± 0.35	36.54 ± 0.24	−0.06	(−0.16 to 0.05)	0.303
Control	36.65 ± 0.49	36.50 ± 0.30	36.48 ± 0.21		Reference
p-value^a	0.441	0.176	0.584
Heart rate (bpm)
Treatment	90.86 ± 19.27	76.46 ± 14.82	76.43 ± 16.93	−0.04	(−14 to 0.07)	0.487
Control	90.63 ± 15.53	75.36 ± 11.66	74.83 ± 10.84		Reference
p-value^a	0.956	0.730	0.804
Systolic blood pressure (mmHg)
Treatment	135.97 ± 25.54	118.11 ± 15.58	123.86 ± 10.57	1.58	(−3.76 to 6.91)	0.563
Control	129.69 ± 15.12	122.19 ± 16.30	121.67 ± 10.04		Reference
p-value^a	0.221	0.285	0.658
Diastolic blood pressure (mmHg)
Treatment	79.49 ± 14.31	72.69 ± 10.32	76.29 ± 11.34	1.08	(−2.55 to 4.72)	0.559
Control	75.88 ± 12.77	70.50 ± 11.38	69.00 ± 8.29		Reference
p-value^a	0.282	0.400	0.124
Mean arterial pressure (mmHg)
Treatment	98.31 ± 16.83	87.83 ± 9.97	92.14 ± 9.64	1.25	(−2.58 to 5.08)	0.523
Control	93.81 ± 11.39	87.73 ± 11.77	86.56 ± 7.67		Reference
p-value^a	0.201	0.970	0.181
Respiratory rate (bpm)
Treatment	20.06 ± 0.58	19.94 ± 0.34	20.00 ± 0.00	0.03	(−0.08 to 0.13)	0.622
Control	19.94 ± 0.59	19.89 ± 0.67	19.67 ± 0.78		Reference
p-value^a	0.421	0.670	0.166
Oxygen saturation (%)
Treatment	97.72 ± 1.23	97.67 ± 1.45	97.75 ± 1.59	−0.11	(−0.53 to 0.31)	0.605
Control	97.58 ± 1.46	97.75 ± 1.52	97.81 ± 1.21		Reference
p-value^a	0.664	0.813	0.393

ISSN: 1745-6215